LAMEA Huntington’s Disease Treatment Market

LAMEA Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Country and Growth Forecast, 2024 - 2031

Report Id: KBV-23454 Publication Date: July-2024 Number of Pages: 120
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Latin America, Middle East and Africa Huntington's Disease Treatment Market would witness market growth of 10.8% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Huntington's Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $15,703.9 Thousands by 2031. The Argentina market is showcasing a CAGR of 11.6% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 10.4% during (2024 - 2031).

LAMEA Huntington's Disease Treatment Market

Various factors, including clinical efficacy, safety profiles, regulatory approvals, healthcare infrastructure, patient and caregiver education, and the availability of supportive services, influence the adoption of treatments for Huntington’s Disease (HD). Healthcare providers prioritize treatments that demonstrate efficacy in managing HD symptoms and improving patient outcomes. Therapies that effectively control chorea, dystonia, psychiatric symptoms, and cognitive decline are crucial for adoption.

Also, access to specialized HD clinics and neurology expertise influences treatment adoption. Healthcare facilities equipped to provide comprehensive care, including multidisciplinary teams and supportive services, enhance the delivery and adoption of HD treatments. Education programs are essential for adoption because they provide patients and carers with information about HD, accessible therapies, and helpful resources. Understanding treatment options, potential benefits, and risks facilitates informed decision-making and engagement in care.

With increased funding, Saudi Arabia can expand and modernize its healthcare infrastructure to include specialized neurology clinics and centers of excellence for HD diagnosis, treatment, and research. This expansion improves access to comprehensive care for HD patients across different kingdom regions. According to the ITA, Saudi Arabia contributes 60% of the healthcare expenditures of the Gulf Cooperation Council (GCC) nations, and the Saudi Arabian government continues to prioritize this sector. It was projected to spend $50.4 billion on healthcare and social development in 2023, representing 16.96 percent of its budget and ranking second only to education in terms of expenditure. Thus, the rising healthcare budget in the region is propelling the market's growth.

Free Valuable Insights: The Worldwide Huntington's Disease Treatment Market is Projected to reach USD 805.1 Million by 2031, at a CAGR of 9.0%

Based on Drug Type, the market is segmented into Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies. Based on Age, the market is segmented into Below 50 years and Above 50 years. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

List of Key Companies Profiled

  • Bausch Health Companies, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
  • Hikma Pharmaceuticals PLC
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr.Reddy’s Laboratories Ltd.
  • Neurocrine Biosciences Inc.
  • Pfizer, Inc.
  • F.Hoffmann-La Roche Ltd.

LAMEA Huntington’s Disease Treatment Market Report Segmentation

By Drug Type

  • Approved Drugs
    • Tetrabenazine
    • Deutetrabenazine
  • Offlabel Drugs

By Distribution Channel

  • Hospital Pharmacies
  • Drug Store & Retail Pharmacies
  • Online Pharmacies

By Age

  • Below 50 years
  • Above 50 years

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo